---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-010296"
form_type: "8-K"
ticker: "BLGO"
cik: "0000880242"
company_name: "BIOLARGO, INC."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:44:16.943293+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioLargo reports record 2024 revenues of $17.8M, up 45% YoY; net loss narrows 6%

## Summary
- Revenue $17.779M, up 45% from 2023; tenth consecutive year of revenue growth.
- Net loss $4.347M, down 6% YoY; $3.490M of loss from Clyra Medical operations.
- Issued 42% fewer shares in 2024 vs 2023; cash and equivalents $3.548M at Dec 31.
- Clyra surgical irrigation products progressing toward national rollout with distribution partner.
- Non-cash expenses (stock/options) $2.479M, representing 57% of net loss.

## SEC filing metadata
- accession: 0001437749-25-010296
- form_type: 8-K
- ticker: BLGO
- cik: 0000880242
- company_name: BIOLARGO, INC.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/880242/000143774925010296/0001437749-25-010296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/880242/000143774925010296/blgo20250331_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-010296
- JSON: https://secwatch.observer/filing/0001437749-25-010296.json
- Plain text: https://secwatch.observer/filing/0001437749-25-010296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.